Lopinavir - Wikipedia
网页Lopinavir is an antiretroviral of the protease inhibitor class. It is used against HIV infections as a fixed-dose combination with another protease inhibitor, ritonavir (lopinavir/ritonavir). [1] It was patented in 1995 and approved for medical use in 2000. [2]
NEJM官方翻译丨中国团队洛匹那韦-利托那韦治疗重症COVID-19
网页迄今为止尚无针对冠状病毒感染的特异性治疗药物。 2003年严重急性呼吸系统综合征（SARS）出现后，对已获批准的药物进行筛选后发现，洛匹那韦（人类免疫缺陷病毒 [HIV]1型的天冬氨酸蛋白酶抑制剂）对引起人类SARS的SARS-CoV病毒具有体外抑制活性。 利托那韦与洛匹那韦联用可通过抑制细胞色素P450来延长洛匹那韦的血浆半衰期。 2004年发表的一项开放标签研究提示，与仅接受利巴韦林治疗的历史对照组相比，利巴韦林加用 …
Efficacy and safety of lopinavir-ritonavir in COVID-19: A …
网页2021年4月20日 · Lopinavir-ritonavir is a repurposed drug for coronavirus disease-2019 (COVID-19). In this study, a pooled effect of lopinavir-ritonavir on mortality, virological cure, radiological improvement and safety profile in COVID-19 …
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid ...
网页2020年3月18日 · After the emergence of severe acute respiratory syndrome (SARS) in 2003, screening of approved drugs identified lopinavir, a human immunodeficiency virus (HIV) type 1 aspartate protease inhibitor...
Efficacy and Safety of Lopinavir/Ritonavir for Treatment of COVID …
网页2020年11月28日 · Lopinavir-ritonavir (LPV/RTV) is a protease inhibitor and nucleoside analog combination used for human immunodeficiency virus (HIV-1) and was also thought to be a potential treatment for COVID-19 [8], as its therapeutic value in the treatment of COVID-19 was assessed by in-vitro studies that claimed inhibition of …
Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A …
网页2020年6月30日 · Lopinavir (LPV) is an antiretroviral protease inhibitor used in combination with ritonavir (booster) in HIV infection therapy and prevention. LPV is a peptidomimetic HIV type 1 aspartate protease inhibitor that acts by binding to its catalytic site, thereby, preventing the cleavage of viral polyprotein precursors into mature, functional ...
Lopinavir: Uses, Interactions, Mechanism of Action - DrugBank …
网页Lopinavir is an antiretroviral protease inhibitor used in combination with other antiretrovirals in the treatment of HIV-1 infection. 7 Lopinavir is marketed and administered exclusively in combination with ritonavir - this combination, first marketed by Abbott under the brand name Kaletra in 2000, is necessary due to lopinavir's poor oral ...
Lopinavir–ritonavir in patients admitted to hospital with COVID …
网页In patients admitted to hospital with COVID-19, lopinavir–ritonavir was not associated with reductions in 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death. These findings do not support the use of lopinavir–ritonavir for treatment of patients admitted to hospital with COVID-19.
Lopinavir-ritonavir for COVID-19: A living systematic review
网页2020年7月15日 · For severe and critical patients with COVID-19, lopinavir/ritonavir might play a role in improving outcomes, but the available evidence is still limited. A substantial number of ongoing studies should provide valuable evidence to inform researchers and decision-makers soon.
Lopinavir–ritonavir in severe COVID-19 - Nature Medicine
网页2020年4月9日 · A randomized, controlled, open-label trial of lopinavir–ritonavir in patients with severe COVID-19 shows no benefit for the primary endpoint beyond standard care but shows benefit for some ...